排序方式: 共有122条查询结果,搜索用时 15 毫秒
2.
Sorafenib and azacitidine as salvage therapy for relapse of FLT3‐ITD mutated AML after allo‐SCT 下载免费PDF全文
3.
V. Lj. Lazarevic 《Journal of internal medicine》2021,290(2):279-293
The definition of older age in AML is arbitrary. In the context of the clinical studies, it starts with age ≥60 or ≥65 years and in recent years ≥70 or 75, depending on the selection of the studied population. In clinical practice, with older age, we often mean that the patient is unfit for intensive chemotherapy. Higher age overlaps with categories such as worse performance status, unfitness, comorbidities, poor-risk cytogenetics, adverse mutation patterns, age-related clonal haematopoiesis and specific disease ontogeny. Intensive induction therapy can result in prolonged overall survival, at least in a subset of elderly patients aged up to 75 years despite the reluctance of some physicians and patients to use treatment regimens perceived as toxic. Venetoclax and azacitidine combination is the new standard of comparison for persons unfit for intensive therapy. New oral hypomethylating agent CC-486 as maintenance therapy led to a prolonged overall survival in a randomized trial of patients ≥55 years of age who were in first complete remission, but not eligible for allogeneic stem cell transplantation. Any therapy is better than no therapy, but a substantial proportion of older patients still receive only palliative care. Making a decision for AML diagnosed in older age should be individualized and shared through the dialog with the patient and relatives or cohabitants, considering medical issues and social factors including personal goals. Although we are witnesses of the advances in basic research and therapy, we are still a very long way from curing older patients with AML. 相似文献
4.
5.
《Best Practice & Research: Clinical Haematology》2021,34(1):101248
The past three years have witnessed remarkable progress in acute myeloid leukemia (AML). The approval and development of targeted therapies and novel agents has improved outcomes for patients with traditionally poor survival rates. This review has summarized the survival impact of chemotherapy-based regimens in AML and described recent advances that will be of significance in the near future. 相似文献
6.
7.
Susana Vives MD David Martínez-Cuadrón MD Juan Bergua Burgues MD Lorenzo Algarra MD Mar Tormo MD María Pilar Martínez-Sánchez MD Josefina Serrano MD Pilar Herrera MD Fernando Ramos MD Olga Salamero MD Esperanza Lavilla MD José L. López-Lorenzo MD Cristina Gil MD Belén Vidriales MD Jose F. Falantes MD Alfons Serrano MD Jorge Labrador MD María J. Sayas MD María Á. Foncillas MD María L. Amador Barciela MD María Teresa Olave MD Mercedes Colorado MD Adriana Gascón MD María Á. Fernández MD Adriana Simiele MD Manuel M. Pérez-Encinas MD Rebeca Rodríguez-Veiga MD Olga García MS Joaquín Martínez-López MD Eva Barragán PhD Bruno Paiva PhD Miguel Á. Sanz MD Pau Montesinos MD for the PETHEMA Group 《Cancer》2021,127(12):2003-2014
8.
Marino Clavio MD Elena Crisà MD Maurizio Miglino MD Fabio Guolo MD Manuela Ceccarelli MD Flavia Salvi MD Bernardino Allione MD Dario Ferrero MD Enrico Balleari MD Carlo Finelli MD Antonella Poloni MD Carmine Selleri MD Paolo Danise MD Daniela Cilloni MD Anna Angela Di Tucci MD Gianni Cametti MD Roberto Freilone MD Renato Fanin MD Catia Bigazzi MD Renato Zambello MD Monica Crugnola MD Esther N. Oliva MD Riccardo Centurioni MD Francesco Alesiani MD Massimo Catarini Andrea Castelli Antonio Abbadessa Silvana F. Capalbo Pellegrino Musto MD Emanuele Angelucci MD Valeria Santini MD 《Cancer》2021,127(12):2015-2024
9.
10.